• Explore /
  • Poster
  • / Safety and tolerability of olaparib combined with breast radiotherapy in patients with triple-negative breast cancer: Final results of the RADIOPARP phase 1 trial.

Safety and tolerability of olaparib combined with breast radiotherapy in patients with triple-negative breast cancer: Final results of the RADIOPARP phase 1 trial.

Abstract Poster

Authors

null

Pierre Loap

Institute Curie, Department of Radiation Oncology, Paris, France

Pierre Loap , Delphine Loirat , Frederique Berger , Manuel Rodrigues , Louis Bazire , Jean-Yves Pierga , Anne Vincent-Salomon , Fatima Laki , Latifa Boudali , Laurence Raizonville , Veronique Mosseri , Anne Jochem , Mamadou Diallo , Marc-Henri Stern , Alain Fourquet , Youlia M. Kirova

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT03109080

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 534)

DOI

10.1200/JCO.2022.40.16_suppl.534

Abstract #

534

Poster Bd #

306

Abstract Disclosures

Similar Posters

First Author: Youlia M. Kirova

First Author: Anthony J. Chalmers

First Author: Helen Mackay

First Author: Dinu Stefan